Investment Rating - The investment rating for the company is "Buy-A" with a 6-month target price of 20.65 CNY, compared to the current stock price of 18.85 CNY [4]. Core Insights - The company reported a revenue of 2.059 billion CNY in 2025, an increase of 18.69% year-on-year, but the net profit attributable to shareholders decreased by 71.61% to 113 million CNY [1][2]. - The decline in profit is attributed to several factors, including market downturns for certain products, increased amortization from acquisitions, and a decrease in gross margin due to intensified market competition and regulatory changes [1][2]. - The company achieved a record high in plasma collection, totaling 662.31 tons in 2025, a growth of 5.03% year-on-year, with significant contributions from the newly acquired Green Cross [3][8]. Summary by Sections Financial Performance - In 2025, the blood products business (parent company) generated 1.414 billion CNY in revenue, a decrease of 4.08%, and a net profit of 161 million CNY, down 60.37% [2]. - The blood products business (Green Cross China) saw a revenue increase of 540.52% to 258 million CNY, with net profit soaring by 42369.44% to 26 million CNY due to full-year consolidation [2]. - The pharmaceutical distribution business (Glenmark) reported a revenue of 198 million CNY, up 9708.34%, but incurred a net loss of 8 million CNY [2]. Growth Drivers - The company successfully acquired 100% of Green Cross Hong Kong in November 2024, enhancing its operational capacity with additional plasma collection stations [3]. - The company plans to focus on expanding its plasma collection network and improving operational efficiency in existing stations [7]. Product Development - The company has made significant progress in R&D, with new products such as 10% human immunoglobulin and tetanus immunoglobulin receiving approval in 2025 [8]. - Several projects are in clinical trials, including C1 esterase inhibitor and subcutaneous human immunoglobulin, which are expected to enhance the company's competitive edge [8].